8
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T6041 | Oprozomib | PR-047,ONX 0912 | Proteasome , Autophagy |
Oprozomib (PR-047) (ONX 0912) , an inhibitor for CT-L activity of 20S proteasome β5(IC50=36 nM)/LMP7(IC50=82 nM), is orally bioavailable. Oprozomib also has potential antineoplastic activity. | |||
T6029 | ONX-0914 | ONX0914,PR-957,ONX 0914 | Proteasome , HIV Protease , Antibacterial |
ONX-0914 (PR-957) is an effective and specific immunoproteasome inhibitor, which has minimal cross-reactivity for the constitutive proteasome. | |||
T11924 | M3258 | LMP7-IN-1 | Proteasome |
LMP7-IN-1 may used in the research of inflammatory and autoimmune diseases, neurodegenerative diseases, proliferative diseases and cancer, is an inhibitor of immunoproteasome (LMP7). | |||
T37420 | Ac-ANW-AMC | Ac-ANW-AMC,Ac-Ala-Asn-Trp-AMC | |
Ac-ANW-AMC is a fluorogenic substrate for the β5i/LMP7 subunit of the 20S immunoproteasome. [1] Upon cleavage, 7-amino-4-methylcoumarin (AMC) is released and its fluorescence can be used to quantify the activity of the β... | |||
T37419 | Zetomipzomib | ||
KZR-616, a first-in-class inhibitor of the immunoproteasome, selectively targets the LMP7 (IC50: 39/57 nM=hLMP7/mLMP7) and LMP2 (IC50: 131/179 nM=hLMP7/mLMP7) subunits of the immunoproteasome. KZR-616 has the potential f... | |||
T15678 | KZR-504 | Proteasome | |
KZR-504 is a selective inhibitor of immunoproteasome low molecular mass polypeptide 2 (LMP2) (IC50s: 51 nM, 4.274 μM for LMP2 and LMP7, respectively). | |||
T39653 | Zetomipzomib maleate | Zetomipzomib maleate,KZR-616 maleate | |
Zetomipzomib maleate (KZR-616), a novel immunoproteasome inhibitor, effectively and selectively inhibits the LMP7 subunit (hLMP7/mLMP7 IC50: 39/57 nM) and LMP2 subunit (hLMP7/mLMP7 IC50: 131/179 nM) of the immunoproteaso... | |||
T73986 | ONX-0914 TFA | ||
ONX-0914 (PR-957) TFA is a selective, noncompetitive, irreversible inhibitor targeting the chymotrypsin-like subunit (LMP7) of the immunoproteasome, effectively blocking cytokine production and mitigating the progression... |